cell transplantation

[Jasper Therapeutics, Inc. (Business Wire, Inc.)] Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes.

[Cytotherapy] Researchers highlighted the importance of regional public cord blood banks in fulfilling hematopoietic stem cell transplantation needs, especially in countries with significant genetic diversity.

[Blood Advances] Researchers evaluated outcomes in patients with hematological malignancy treated with myeloablative conditioning prior to haplo or umbilical cord blood hematopoietic stem cell transplantation.

[Mucosal Immunology] Researchers generated dendritic cell-specific Ripk1−/− mice in a genetic background with loss of RIPK1 kinase activity and found that the mice developed spontaneous colonic inflammation characterized by increased neutrophil and Ly6C+ monocytes.

[Stem Cell Research & Therapy] Scientists discuss and explain the most recent advances in chimeric antigen receptor (CAR) T cell-based therapies targeting acute myeloid leukemia (AML) antigens and review the results of preclinical and clinical trials.

[Blood Reviews] Scientists summarize the current knowledge about statins and other agents used as endothelial protectants. They propose further studies using statins for prophylaxis and prevention of end-organ damage related to extensive endothelial dysfunction in hematopoietic stem cell transplantation and chimeric antigen receptor-T cells.